Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials

Data source: Bayside Health Alfred Powertrials list of active trials
Last updated: 3 September 2026

Clear filter
682 clinical trials found
Clinical trials

INTERVENE

An ALLG Phase 2 study to Investigate Novel Triplets to Extend Remission with VENetoclax in Elderly (INTERVENE) Acute Myeloid Leukaemia (ACTRN12619001655134)

Currently recruiting

IOS-1002

A Phase 1a/1b, first-in-human, open-label, non-randomized, multicenter, dose-escalation and cohort expansion study to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of IOS-1002 administered alone and in combination with a PD-1 monoclonal antibody in advanced solid tumors (NCT05763004)

Currently recruiting

IPSEN Meranti

A multicentre, randomised, double-blind, placebo-controlled, dose escalation and dose finding phase II study to evaluate the safety and efficacy of IPN10200 in the prevention of episodic or chronic migraine in adults (NCT06625060)

The purpose of this study is to investigate the safety and effectiveness of IPN10200, in participants living with migraines. The information gathered from this study will contribute to our understanding of how this study treatment may benefit individuals suffering from migraines. Participants will be assigned the study drug or placebo. Following the confirmation of safety in Step 1 by the DMC, up to two doses of IPN10200 will be compared against placebo in parallel groups in Step 2. 
Participants who meet all study criteria will be randomly assigned to one of three intervention groups: Dose A, Dose B or a placebo. Each participant will be in the study for 40 to 44 weeks including a screening period of 6 weeks (± 2 weeks).
Participants who fulfill all study criteria, will be included and will receive the study treatment at Day 1 (D1), followed by a follow up period of 36 weeks. All the participants will have to attend 7 onsite visits during the study including Screening visit, Day 1, and follow up visits at study site. Participants will also have remote visits (about 7 phone calls in total).

Currently recruiting

IRONMAN

International Registry for Men with Advanced Prostate Cancer (IRONMAN) (NCT03151629)

Currently recruiting

ISB1442-101

A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma(ACTRN12622000856718)

Currently recruiting

IVIG Therapy in Lung Tx

A Randomised Double-blind Placebo-controlled Pilot Study of Intravenous Immunoglobulin Replacement Therapy in Lung Transplantation (ACTRN12618001394235)

No longer recruiting

IVY-P3-24-021

A Phase 3, open-label, randomized 2-arm study comparing the clinical efficacy and safety of niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma (NCT06388733)

Currently recruiting

JADE

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (NCT06256588)

Currently recruiting

KarMMa-9

A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants with Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9) (NCT06045806)

Currently recruiting

KER-012-A201

A Randomised, Phase 2, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of KER-012 in Combination with Background Therapy in Adult Participants with Pulmonary Arterial Hypertension (NCT05975905)

No longer recruiting

Keto eCoach

The Keto eCoach Program: a multimodality digital health intervention to aid the delivery of ketogenic diet therapy for epilepsy (ACTRN12624000486527)

Currently recruiting

KIBI

Ketamine Sedation in Acute Traumatic Brain Injury: A Randomised Pilot Feasibility Study (ACTRN12623000594628)

Currently recruiting

KLN-001 inMMyCAR

A Phase 1 Study to Evaluate the Safety of a Novel, In Vivo Gene Therapy to Create Anti-BCMA CAR-T Cells in Patients with Relapsed and Refractory Multiple Myeloma (NCT07075185)

KLN-1010 is a one-time treatment for Relapsed and Refractory Multiple Myeloma. KLN-1010 is a third generation, self-inactivating (SIN), replication incompetent, recombinant lentivirus (LVV) that contains modified envelope proteins to enable specific cell targeting and gene transfer of a fully human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) in vivo.
Coming soon

KRT-232-101

An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post-PV-MF), Or Post–Essential Thrombocythemia MF (Post–ET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor (NCT03662126)

Currently recruiting

KRYSTAL-10

A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (NCT04793958)

No longer recruiting

KT-US-656-0601

A Phase 1 Open-label, Single Arm, Multicenter Study Evaluating the Safety and Efficacy of KITE-197 in Subjects with Relapsed or Refractory Large B-cell Lymphoma (NCT06079164)

Currently recruiting

Ladera

Evaluation of the Safety and Performance of the Ladera Medical Suture-Mediated Large Bore Closure [LBC] System - The Ladera LBC Feasibility Study (NCT06358157)

No longer recruiting

LASER

Treatment of Locally Advanced NSCLC with Stereotactic ablativE Radiotherapy (LASER) (ACTRN12619001186145)

Currently recruiting

Lavender D346BC00001

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus who are Refractory and/or Intolerant to Antimalarial Therapy (NCT06015737)

The D346BC00001 study is designed to evaluate the efficacy and safety of anifrolumab in adults with chronic and/or subacute lupus erythematous. 
Participants receive either trial medication or a placebo (something that looks like the trial drug but has no effect on the body), both administered weekly as injections into the skin (subcutaneous injections). The treatment period will be approximately 52 weeks with all participants moving to active treatment (receiving treatment drug) after Week 24.
 

Currently recruiting

LBS-007-CT01

A Phase 1/2, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of LBS-007 in Patients with Relapsed or Resistant Acute Leukaemias (NCT05756322)

Currently recruiting
17 18 19 20 21